Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
UPBthis companyUpstream Bio, Inc.	$3.41	-10.21×	4.3×	512.3×	-9.51×	-107.7%	100.0%	-5618.8%	-5026.0%	-42.2%	-47.0%	-9.1%	0×	0.7×	0×	26.15×	0.0%	2	7.6	2	C+
AMLXAmylyx Pharmaceuticals, Inc.	$29.48	-7.9×	3.74×	0×	-6.39×	-91.8%	0.0%	0.0%	0.0%	-47.4%	-49.3%	-10.8%	0.02×	1.53×	0×	14.27×	0.0%	3	77.91	2	C
NTLAIntellia Therapeutics, Inc.	$11.85	-2.36×	1.45×	14.4×	-2.3×	-249.6%	76.5%	-651.7%	-609.9%	-61.5%	-57.7%	-36.4%	0.14×	0.16×	0×	5.08×	0.0%	4	2.17	2	C
NVAXNovavax, Inc.	$10.64	2.47×	-8.52×	0.97×	2.23×	-870.5%	93.7%	50.1%	39.2%	-344.7%	78.0%	-23.0%	-1.95×	0.02×	24.98×	2.13×	0.0%	1	-5.75	2	B-
RLAYRelay Therapeutics, Inc.	$19.69	-5.25×	2.56×	94.54×	-5.13×	-104.1%	76.8%	-1971.6%	-1800.6%	-48.8%	-50.5%	-16.2%	0.06×	0.19×	0×	22.61×	0.0%	3	26.32	2	C
SNDXSyndax Pharmaceuticals, Inc.	$9.40	-6.39×	28.16×	10.56×	-8.07×	-0.0%	96.0%	-158.4%	-165.6%	-441.6%	-66.6%	-17.8%	5.36×	-0.84×	-8.08×	4.4×	0.0%	3	-1.72	1	D+
Peer median	—	-5.25×	2.56×	10.56×	-5.13×	-104.1%	76.8%	-158.4%	-165.6%	-61.5%	-50.5%	-17.8%	0.06×	0.16×	0×	5.08×	0.0%	3	2.17	2	—